|Titre :||Acceptability of formulations and application methods for vaginal microbicides among drug-involved women: results of product trials in three cities|
|Auteurs :||T. M. HAMMETT ; T. H. MASON ; JOANIS C. L. ; S. E. FOSTER ; HARMON P. ; R. R. ROBLES ; H. A. FINLINSON ; FEUDO R. ; VINING-BETHEA S. ; JETER G. ; K. H. MAYER ; P. DOHERTY-IDDINGS ; SEAGE G. R., 3RD.|
|Type de document :||Périodique|
|Année de publication :||2000|
|Note générale :||
Sexually Transmitted Diseases, 2000, 27, (2), 119-126
|Discipline :||MAL (Maladies infectieuses / Infectious diseases)|
Thésaurus TOXIBASEREDUCTION DES RISQUES ; SEXE FEMININ ; VIH ; PREVENTION ; SEXUALITE ; PRODUIT ILLICITE
|Résumé :||BACKGROUND AND OBJECTIVES: Female-controlled methods of HIV prevention, such as vaginal microbicides, are urgently needed, particularly among drug-involved women. Acceptability research is critical to product development. GOAL: To assess the acceptability of forms and application methods for future microbicides. DESIGN: Eighty-four drug-involved women were introduced in groups to three lubricant products, asked to try each for 3 weeks, and scheduled for individual follow-up interviews. RESULTS: Participants and their partners felt positive about the products, and expressed willingness to use microbicides if they were shown to be effective against HIV. Women agreed on product characteristics that influenced their reactions (e.g. ease of insertion, degree of "messiness"), but often disagreed on whether their reactions to these characteristics were positive or negative. CONCLUSION: Development of acceptable and effective HIV-prevention products depends on understanding the interaction between characteristics of the products and the characteristics and perceptions of women. Levels of sexual risk and acceptability factors based on drug-use patterns, race and ethnicity, culture, age, and types and attitudes of male partners suggest that a "one size fits all" approach will not win broad acceptance among drug-involved women. (Author' s abstract)|
|Domaine :||Drogues illicites / Illicit drugs|
|Refs biblio. :||39|
Abt Associates Inc, Cambridge, Massachusetts 02138-1168.
Etats-Unis. United States.
|Centre Emetteur :||13 OFDT|